70916 Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices

misconduct. With respect to the

material identified in Paragraph 6, Dr.

Dreyer admitted that he fabricated the

21 chromatograms contained in the

magneto-optical computer disk that he

provided to institutional officials after

questions were raised about his

research. Dr. Dreyer further admitted

that the fabrication of the data on the

disk amounts to scientific misconduct.

Dr. Dreyer has voluntarily agreed for

a period of ten (10) years, beginning on

November 15, 2000, to exclude himself

from:

(1) Any contracting or subcontracting

with any agency of the United States

Government and from eligibility for, of

involvement in, nonprocurement

transactions (e.g., grants and cooperative

agreements of the United States

Government as defined in 45 CFR Part

76 (Debarment Regulations);

(2) Serving as a mentor to any

graduate student, fellow, or other

individual who applies for or receives

Federal funding; and

(3) Serving in any capacity to PHS,

including but not limited to service on

any PHS advisory committee, board,

and/or peer review committee, or as a

consultant.

The above voluntary exclusion,

however, does not apply to Dr. Dreyer’s

practice of clinical medicine as a

licensed practitioner or to Federal funds

used for purposes of teaching or training

medical students, residents, or fellows,

in clinical medical matters.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative

Oversight, Office of Research Integrity,

5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris Pascal,

Director, Office of Research Integrity.

[FR Doc. 00–30236 Filed 11–27–00; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Statement of Organization, Functions,

and Delegations of Authority

Part C (Centers for Disease Control

and Prevention) of the Statement of

Organizations, Functions, and

Delegations of Authority of the

Department of Health and Human

Services (45 FR 67772–76, dated

October 14, 1980, and corrected at 45 FR

69296, October 20, 1980, as amended

most recently at 65 FR 68144, dated

November 14, 2000) is amended to

revise the functional statement of the

Division for AIDS, STD, and TB

Laboratory Research (DASTLR),

National Center of Infections (NCID).

Section C–B, Organization and

Functions, is hereby amended as

follows:

Delete the functional statement for the

Division of AIDS, STD and TB

Laboratory Research (HCRN) and insert

the following:

Division of AIDS, STD and TB

Laboratory Research (HCRN). (1)

Develops and evaluates laboratory

methods and procedures for the

diagnosis and characterization of

infections caused by human

immunodeficiency virus (HIV) and

other retroviruses, other sexually

transmitted diseases (STDs), and

mycobacteria including Mycobacterium

tuberculosis; (2) provides laboratory

support for the surveillance,

epidemiologic, and clinical activities of

the National Center for HIV, STD, and

TB Prevention (NCHSTP); (3) conducts

applied research on the pathogenesis of

and the immune mechanisms that occur

in microbial infections; (4) conducts

laboratory studies of hemophilia and

other coagulating disorders; (5) provides

reference laboratory services and assists

in standardizing and providing

laboratory reagents; (6) serves as a

World Health Organization

Collaborating Center; (7) conducts

epidemiologic studies of HIV-infected

and uninfected persons with

hemophilia and their families; (8) assists

in designing, implementing, and

evaluating prevention and counseling

programs for HIV-infected persons with

hemophilia and their families; and (9)

coordinates research on opportunistic

infections occurring in HIV-infected

persons.

Dated: November 15, 2000.

Jeffrey P. Koplan,

Director.

[FR Doc. 00–30217 Filed 11–27–00; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1599]

Agency Information Collection

Activities; Proposed Collection;

Comment Request; Use of ImpactResistant Lenses in Eyeglasses and

Sunglasses

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

opportunity for public comment on the

proposed collection of certain

information by the agency. Under the

Paperwork Reduction Act of 1995 (the

PRA), Federal agencies are required to

publish notice in the Federal Register

concerning each proposed collection of

information, including each proposed

extension of an existing collection of

information, and to allow 60 days for

public comment in response to the

notice. This notice solicits comments on

recordkeeping requirements to insure

public health and safety for

manufacturers of impact-resistant lenses

used in eyeglasses and sunglasses.

DATES: Submit written or electronic

comments on the collection of

information by January 29, 2001.

ADDRESSES: Submit written or electronic

comments on the collection of

information to http://

www.accessdata.fda.gov/scripts/oc/

dockets/edockethome.cfm. Submit

written comments on the collection of

information to the Dockets Management

Branch (HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852. All

comments should be identified with the

docket number found in brackets in the

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Peggy Schlosburg, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1223.

SUPPLEMENTARY INFORMATION: Under the

PRA (44 U.S.C. 3501–3520), Federal

agencies must obtain approval from the

Office of Management and Budget

(OMB) for each collection of

information they conduct or sponsor.

‘‘Collection of information’’ is defined

in 44 U.S.C. 3502(3) and 5 CFR

1320.3(c) and includes agency requests

or requirements that members of the

public submit reports, keep records, or

provide information to a third party.

Section 3506(c)(2)(A) of the PRA (44

U.S.C. 3506(c)(2)(A)) requires Federal

agencies to provide a 60-day notice in

the Federal Register concerning each

proposed collection of information,

including each proposed extension of an

existing collection of information,

before submitting the collection to OMB

for approval. To comply with this

requirement, FDA is publishing notice

of the proposed collection of

information set forth in this document.

With respect to the following

collection of information, FDA invites

comments on: (1) Whether the proposed

collection of information is necessary